New drug shows promise in shrinking lung scars in IPF patients
NCT ID NCT05621252
First seen Nov 01, 2025 · Last updated May 03, 2026 · Updated 33 times
Summary
This study tested a new drug called PLN-74809 in 10 people with idiopathic pulmonary fibrosis (IPF), a disease that causes lung scarring. The goal was to see if the drug could reduce scarring in the lungs over 12 weeks. Participants took either the drug or a placebo, and doctors used a special imaging scan to measure changes in collagen, a key part of scar tissue.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
Conditions
Explore the condition pages connected to this study.